Hikma Pharmaceuticals Plc Total Voting Rights (9718D)
November 02 2020 - 7:20AM
UK Regulatory
TIDMHIK
RNS Number : 9718D
Hikma Pharmaceuticals Plc
02 November 2020
Hikma Pharmaceuticals PLC
(the Company)
Total Voting Rights and Capital
LONDON, 2 November 2020 - In accordance with the UK Financial
Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals
PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that, in accordance with the Disclosure
Guidance and Transparency Rules ('the Rules'), we notify the market
of the following:
As at 31 October 2020, the issued share capital of the Company
comprised of 230,496,614 ordinary shares with voting rights. This
figure excludes 12,833,433 Shares held in treasury.
The figure of 230,496,614 may be used by shareholders (and
others with notification obligations) as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREADFAEAEEFFA
(END) Dow Jones Newswires
November 02, 2020 08:20 ET (13:20 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024